Objective: A case control study has reported a 60% diuretics ± other treatments (but not including one of the index drugs) provided a reference group with a relahigher risk of myocardial infarction in hypertensives treated with a calcium channel blocker (CCB The results in the unmatched case control analysis were unmatched, plus two longitudinal studies from 1 year of presentation, one for all subjects given a CCB for more also similar. The longitudinal study comparing all those treated for over 1 year with a CCB with all other treatthan 1 year compared with those not given this drug, and the second comparing survival on the different ments showed a RR for total mortality of 1.03 (95% CI 0.85-1.25). The longitudinal study of total mortality drugs initially given between 3 and 12 months of follow-up.
Introduction
increased risk with nifedipine, a nonsignificant A case control study has reported a 60% higher risk increase with diltiazem, and no increase with veraof myocardial infarction in hypertensives treated pamil. 3 No randomised trials have been completed with a calcium channel blocker (CCB) compared that compare morbidity and mortality with CCBs either with a diuretic or with a beta-blocker (BB), with other active treatment, although the NHLBI irrespective of a prior diagnosis of cardiovascular report stated '. . . the Multicenter Isradipine Diuretic disease. 1 The increased risk associated with nifedipAtherosclerosis study (MIDAS). . . showed . . . a ine was 31%, for diltiazem 63% and for verapamil trend towards a higher rate of cardiovascular events 61%. A statement from the National Heart, Lung and in the isradipine (a short acting dihydropyridine) Blood Institute 2 (NHLBI) also mentioned a study in compared to the diuretic group'. 2, 4 No randomised trial has yet been published for CCBs in hypertensive subjects in general but an Correspondence: Professor CJ Bulpitt, Division of Geriatric Medialternatively-allocated study, the Shanghai trial cine, Royal Postgraduate Medical School, Hammersmith Hospital, Du Cane Road, London W12 0NN, UK of nifedipine in the elderly (STONE), reported a relative risk (RR) of cardiovascular events on nifedipatients referred to the hypertension clinics or pine of 0.40 (95% CI 0.25-0.64). 5 identified by the general practitioners were included Concern about the use of CCBs in hypertension is irrespective of level of blood pressure (BP). However not centred around their efficacy in lowering blood information was lacking on smoking habits in 13% pressure (BP) but around the possibility that they and untreated BP in 42%. Treated BP was available predispose to coronary events. It is suggested that in 73% of patients and was averaged over 3-12 they increase mortality in subjects who have susmonths from presentation for each subject. The tained an MI and meta-analyses of trials post myoreadings over the first 3 months were excluded as cardial infarction have suggested an increased risk this was the period during which treatment was usuof mortality by about 16% with short acting dihydally stabilized. The great majority of the patients ropyridine CCBs.
2,6-8 A dose-related increase has (95%) were attending a clinic at one of the following been reported, with an increased risk with a dose hospitals: King's College Hospital, London; Hamof nifedipine of 80 mg daily or greater. 9 The metamersmith Hospital, London; John Radcliffe Hospital, analyses have not suggested an increased mortality Oxford; City Hospital, Birmingham; and Aberdeen with non-dihydropyridine CCBs such as diltiazem Royal Infirmary. The remaining 5% were managed and verapamil. The NHLBI statement therefore sugby general practitioners in Kentish Town (London), gested that 'short acting nifedipine should be used Harlow, Oxford, and Norwich. with great caution (if at all), especially at higher Survival has been determined for a maximum of doses, in the treatment of hypertension, angina and 22 years (average, 11 years). The causes of death and MI'. 2 The problem is two-fold, the use of meta-analyrisk factors for survival have been previously pubsis of data from randomised controlled trials to lished.
13-14
determine the place of CCBs post myocardial infarcThere were 1793 deaths (33% of the men, 24% of tion, and the employment of observational pharmacthe women). Death certificates were coded according oepidemiological data to determine the adverse to the eighth revision of the International Classieffects, if any, of CCBs in hypertension where no fication of Diseases for any mention of a cause of trial data are available. The latter problem is more death. The codes for cardiovascular disease were difficult and has been widely debated.
10-12 The 3900-4589 and 7950-7959, ischaemic heart disease present analysis from the Department of Health (IHD) 4100-4149, and stroke 4300-4389. Hypertension Care Computing Project (DHCCP) Four main analyses were performed. observational database has been undertaken with a (1) Case control studies of those dying from first, view to corroborating or refuting the reports con-IHD, and second, any cardiovascular cause comcerning the use of CCBs in hypertension.
pared with up to three controls alive at the time the case died and on an index treatment prior to case death; matched on age (within ±10 years), gender,
Patients and methods
clinic attended, and year of presentation (within ±5 The DHCCP is a multi-center computer-based obseryears). Additional adjustments were also made; cigavational study of patients being treated for hypertenrette smoking habit at presentation (ever smoked vs sion in the UK. It started in 1971 and currently connever smoked), treated BP and also for age and year tains records of 11 663 patients recruited up to 31 of presentation as the matching limits were broad. December 1987. [13] [14] [15] Patients entered the system on There were 998 cases who died from a cardiovascupresentation to one of the hospital hypertension lar cause and 1978 controls (646 and 1288 after all clinics or general practices involved in the study. adjustments). A total of 617 cases died of IHD and Details of presentation and subsequent attendance had 1550 controls (399 and 1044 after all were recorded. The Office of Population Censuses adjustments). and Surveys holds a flagged record of all these
The most important reasons for exclusion were: patients and gives notification of any emigration or not received one of the index treatments (3767); deaths.
received more than one index drug apart from a A total of 1477 patients were excluded as they diuretic (908); spare controls (3199); and treated BP were recruited after the last compilation of the basic not known (515). database, and in 13 either gender or age were not (2) A case control study as above but without known. A further total of 6406 had a record of treatmatching and with adjustment for age, gender, ment with one or more of the following: a CCB, a smoking at presentation, previous cardiovascular beta adrenergic blocking drug (BB), methyldopa, an disease, year of presentation and clinic attended. angiotensin-coverting enzyme (ACE) inhibitor or a This analysis has the advantage of including all diuretic [the index drugs]; of these, 1637 (26%) available controls. received a CCB, 5373 (84%) a diuretic, 1887 (29%) (3) A longitudinal study of survival from 1 year methyldopa, 743 (12%) a BB, and 696 (11%) an ACE after presentation in the 785 subjects given a CCB inhibitor. These treatments may have been taken for more than 1 year, and 8543 subjects never given concurrently or consecutively for a variable length a CCB. The Cox proportional hazards model 15 was of time prior to death and not necessarily just before used to determine the association between mortality death. Patients who received only a diuretic totalled and treatment after including age and cigarette 2529 (39%). Of the CCB group, 73% also received smoking, year of presentation, clinic attended, and at some time a diuretic, 23% an ACE inhibitor, 16% systolic BP (SBP) in the model. The availability of methyldopa and 10% a BB. All deaths and their causes were recorded up to 28 February 1993. All information for adjustment reduced the number in this analysis to 579 who had received a CCB and with a diuretic (21-23%) (P Ͻ 0.0001 for an overall comparison between groups). 4360 who had not.
(4) A longitudinal survival of patients in the index Those given methyldopa, with or without a diuretic, were older than those in the other groups, treatment groups defined in (1) above. However, treatment had to be initially prescribed between 3 had higher untreated pressures and had been enrolled earlier. Similarly intergroup differences and 12 months of follow-up, and survival was determined from 1 year of follow-up. Of 805 subjects were observed for the proportion of males and average treated BP (P Ͻ 0.0001 for all comparisons). The who received additional older antihypertensive drugs (an adrenergic neurone-blocker or a groups were comparable for the percentage of smokers (P = 0.55). Those given a diuretic ± any other vasodilator) were excluded. The Cox proportional hazards model was employed to adjust survival for drugs but not methyldopa, a BB, a CCB, or an ACE inhibitor constituted the reference group with a relaage, gender, smoking at presentation, clinic attended, year of presentation, previous cardiotive risk of one. Table 2 gives the results of case control study vascular disease and treated SBP. The data were similarly adjusted for untreated SBP.
number (1) . The 617 cases were similar to the 1550 controls except that 43% of the cases smoked cigaThe CCBs employed were nifedipine (short acting and slow release but not the Gastrointestinal Therrettes at presentation compared with 31% of the controls and 37% of cases had previous cardioapy System (GITS)), diltiazem and verapamil. Data on individual drugs were not available for this vascular disease against 19%. Average untreated and treated pressures were higher in cases at report.
199/115 and 165/95 mm Hg respectively, compared with 190/112 and 157/93 mm Hg for controls.
Results
The unadjusted RR for IHD mortality was increased for the patients who received methyldopa The drugs of interest were CCBs, diuretics, BBs, methyldopa and ACE inhibitors, and were desigplus a diuretic (RR = 1.43) but this excess risk was not present after adjustment for age, year of presennated the index drugs. Table 1 gives the characteristics at first clinic presentation of the nine exclusive tation, smoking at presentation, treated SBP and previous cardiovascular disease. For all cardiovascular drug groups that formed the populations contributing to analyses (1), (2) and (4). deaths patients given methyldopa had a high unadjusted RR of 1.40 (P Ͻ 0.05) without a diuretic, and The groups prescribed mainly a diuretic alone, methyldopa alone, BB alone and ACE inhibitor 1.75 (P Ͻ 0.001) with a diuretic. After adjustment for other factors the excess RRs were 1.16 and 1.30 alone had a low percentage of previous cardiovascular disease (14 -18%) compared with those who respectively. The prescription of a CCB without a diuretic was associated with an adjusted risk of IHD received a CCB or a combination of an index drug Table 3 (analysis 4) compares the survival of different groups from 1 year of follow-up according to 1.50 for total cardiovascular mortality). Similarly the small number on an ACE inhibitor without a the treatment given at 1 year. Patients on adrenergic neurone blocking drugs or vasodilators were diuretic tended to have high adjusted RRs of 2.14 and 2.23 respectively. Conversely when a BB or ACE excluded. Those on an ACE inhibitor were excluded owing to small numbers. The patients needing inhibitor was given with a diuretic the RRs were between 0.83 and 0.91. additional diuretic treatment, had higher age and sex adjusted death rates. The adjusted RRs were statWhen the data were adjusted for untreated SBP rather than treated BP the number of cases fell to istically above unity for those groups receiving methyldopa, and those receiving a CCB plus a 287 cases and 822 controls. The ACE inhibitor groups were too small to be considered in this analydiuretic and those receiving a BB and a diuretic. sis and of the remaining 12 adjusted RRs, eight were within ± 10% of the results obtained by adjustment Summary of results for treated systolic pressure. The greatest disagreement was CCB (no diuretic) and cardiovascular morWe calculated several estimates of RR for the index treatments (half adjusted for treated BP and half for tality, RR = 1.51 (95% CI 0.83, 2.74) in comparison with RR = 1.05 (95% CI 0.60, 1.84). untreated pressure), and only one in 10 were less than the diuretic reference groups. For methyldopa When all cases and controls were selected without matching but all adjustments made (analysis 2), the treatment and adjustment for treated BP, four adjusted RRs were statistically (Ͻ0.05) in excess of RRs for the prescription of methyldopa in relation to IHD mortality were 1.10 (95% CI 0.70, 1.75) withunity. These were methyldopa + diuretic and total cardiovascular mortality (both analyses 1 and 2), out a diuretic and 1.12 (95% CI 0.84, 1.51) with a diuretic. For CCBs the RRs were 1.20 (95% CI 0.63, and total mortality and methyldopa with and without a diuretic (analysis 4). In general an RR Ͼ2.0 2.28) without, and 1.58 (P Ͻ 0.05, 95% CI 1.05, 2.37) with a diuretic. For a BB without a diuretic the RR was excluded with this drug. For CCB treatment two RRs achieved statistical significance, these were a was 1.81 (95% CI 0.84, 3.93), and 0.81 (95% CI 0.45, 1.45) with a diuretic. The corresponding figures for CCB with a diuretic and IHD mortality (analysis 2), and total mortality and CCB plus a diuretic (analysis death from any cardiovascular cause were methyldopa 1.25 (95% CI 0.85, 1.84), methyldopa + 4). In general an RR of over 2.5 was excluded with this drug, the confidence intervals being wider with diuretic 1.46 (95% CI 1.14, 1.87), CCB 1.02 (95% CI 0.60, 1.71), CCB + diuretic 1.20 (95% CI 0.85, 1.70), the smaller numbers treated. BB treatment revealed one statistically significant RR, BB plus a diuretic BB 1.74 (95% CI 0.85, 3.53), and BB + diuretic 0.99 (95% CI 0.62, 1.56).
and total mortality (analysis 4) but the confidence intervals often encompassed 2.5. Analysis (3) considered those who had received a CCB for at least a year, survival calculated from 1 Table 4 selects the adjusted RRs (adjusted for treated pressure and with a diuretic treated referyear from presentation and adjusted for age, gender, Patients on adrenergic neurone blockers or vasodilators excluded. Treatment groups were mutually exclusive. Adjusted RR 1 = relative risk adjusted for age, gender, smoking at presentation, treated SBP, clinic, year of presentation and previous cardiovascular disease. Adjusted RR 2 = relative risk as for RR 1 but adjusted for untreated SBP, not treated SBP. *P Ͻ 0.05; ***P Ͻ 0.001.
Table 4
Adjusted RRs for three types of analyses that included a CCB, methyldopa and a BB blocker (all groups with and without a diuretic, D) adjusted for treated BP
Analysis (1), (2) or (4)
Calcium channel blocker Methyldopa Beta-blocker The reference groups received a diuretic but not a CCB, methyldopa, BB or Ace inhibitor. Analysis (1) and (2) concerned IHD mortality and analysis (4) concerned total mortality. ence group) for three types of analysis that included ever both randomised groups received digoxin, diuretics and an ACE inhibitor. a CCB, methyldopa and a BB (all groups with and without a diuretic). Analysis (1) and (2) concerned In the treatment of hypertension, the patients are less likely to suffer an adverse consequence from a IHD mortality and analysis (4) total mortality. The RRs varied widely between 0.81 and 2.14 according negative inotropic action, at least at the start of treatment, although a high proportion of hypertensive to method of analysis and drug treatment.
Although the three drug groups, methyldopa, patients die from IHD. Psaty et al 1 reported a risk ratio of 1.62 (95% CI 1.11-2.34) for patients treated CCBs and BBs were associated with higher mortalities than the reference diuretic groups, the results with CCBs compared with a diuretic alone group. Patients needing only a diuretic may be expected to in the three groups were similar.
have less severe hypertension than those given a CCB and might be less likely to have angina at presDiscussion entation. However, Psaty et al found an RR of 1.58 for the use of a CCB alone, and adjusted for many The negative inotropic effects of CCBs and the reflex sympathetic activation of short acting drugs are of variables that reflect the severity of hypertension (smoking, diabetes, pretreatment SBP and duration justifiable concern in the treatment of patients with myocardial infarction and/or angina. Meta-analyses of hypertension). Compared with BBs a similar excess risk was also found with CCBs. suggest that CCBs do not confirm a survival benefit in such patients and may indeed increase the risk When we took a similar case control approach (analysis 1, Table 2 ) and considered both IHD and of coronary death 6, 7, 9 although the Prospective Randomised Amlodipine Survival Evaluation total cardiovascular mortality, the results with a CCB could not be differentiated from those with (PRAISE) 16 trial did not demonstrate an increase in mortality when chronic heart failure patients were methyldopa, BB or ACE inhibitor treatment. In a supplementary analysis we did not employ matched treated with amlodipine rather than placebo. How-controls but included all patients, and adjusted outnon-fatal events are not recorded in the paper). A large number of patients were excluded because of come for age, smoking, treated SBP, previous cardiovascular disease, clinic attended and year of presenpreceding myocardial disease, recent institution of therapy or uncertain compliance with medication. tation. Again no excess mortality for CCBs could be demonstrated compared with methyldopa or a BB.
By contrast our analysis relates to fatal events only and is substantially larger as 1025 deaths are anaIn an analysis of patients taking a CCB for over a year compared with all other patients (analysis 3), lysed in the cohort analysis. We include patients with or without prior cardiovascular disease, irresthere was an RR of 1.03 for total mortality and 1.06 (95% CI 0.79, 1.41) for IHD mortality. In an analysis pective of treatment duration and irrespective of compliance with medication. These factors may add of survival from year 1 and according to treatment at that time (analysis 4, Table 3 ) we identified high confounding elements, but at the same time reflect clinical reality and make our study more akin to an RRs in all groups receiving an index drug plus a diuretic.
intention-to-treat approach.
In essence we find that mortality with CCBs It was apparent that different methods of analysis produce somewhat different results, but overall appears similar to that on methyldopa and BBs, all groups tending to have higher RRs than the diuretic there was little to support the view that CCBs are associated with an increased death rate, unless the reference groups. Methyldopa was widely prescribed in the 1970s but less often in later years. We results on other treatments are ignored.
Some limitations of our analyses must be emphawere careful to allow the selection of controls who could die later from other causes when considering sised. First, and in common with other observational studies, the factors leading to prescribing patients dying of IHD in the early years. We also ensured that the treatment received by the controls a particular drug are multiple, unquantified and a probable confounding influence on outcome. For had to be treatment received prior to the death of the case. This avoided bias from long surviving controls example, if the hypertensive subject develops angina this may be expected to adversely affect outreceiving the most recent drugs and being allocated to these treatment groups. We are not aware of a come, and it is more likely that a CCB will be prescribed because of its anti-anginal effects. We anticimechanism whereby all treatments might adversely affect both IHD and all cause mortality in comparipated that patients at a particularly high risk of MI may have been selected into the CCB groups, but we son with a diuretic. The absence of such a hypothesis, however, does not mean that some unknown were unable to adjust for any new diagnosis of this condition during follow-up and this may partly adverse influence could not be operating. None of our analyses provide any evidence to suggest that explain our findings when the RR tended to be high.
The case control analyses were based on the thiazides should not be retained as first-line therapy in hypertension and it is possible, but unproven, recorded prescription of a particular drug at any time in the past. The drug may not have been taken that we have compared three groups of drugs that have less than ideal properties in the prevention by the patient for any length of time, and eventual mortality may be years later when an adverse event of IHD. There was some evidence that IHD and total carcould less easily be ascribed directly to the drug. Nevertheless patients often remain on the same diovascular mortality was relatively low in the BB + diuretic groups. However this was not supported treatment for long periods of time and the treatment may have long-term effects, either beneficial or by the cohort analysis of total mortality. Nevertheless we have previously reported that the benefits of otherwise. Outcome was also adjusted for information available at time of presentation, for example beta-blockade in hypertensives are least in women and smokers, 18 a finding that agrees with the result smoking at that time, and this may not have been a current risk factor during exposure to a particular of the Medical Research Council (MRC) trial in middle-age 19 and the International Prospective Pridrug. In order to reflect the situation during drug exposure and to maximise the number available for mary Prevention Study in Hypertension 20 (IPPPSH). However, the HAPPHY trial 21 did not report a analyses we mainly report results adjusted for treated rather than untreated pressure. Treated decreased benefit in smokers, but it remains possible that certain groups do not benefit from beta-blockpressure is also more closely related to outcome than untreated pressure. 17 Nevertheless the results ade when prescribed without a diuretic.
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Observational studies are often criticised for the were similar whether adjusted for untreated or treated systolic pressure. Information on treatment non-random initial allocation of drug treatments and their results must be considered with caution. Difbeing received was only available to 1986 and then only if the patient was followed-up until that date.
ferent methods of analysis may also provide a range of answers to the questions posed, as in the present However, we also determined survival from 1 year of follow-up, according to treatment taken at that study. Nevertheless, we have been unable to confirm that the use of CCBs in hypertensive patients is an time and thus avoided some of these problems.
The strength of our analysis is that we have important factor in increasing total or IHD mortality. extended the case control analyses of Psaty et al 1 by considering total, cardiovascular and IHD mortality, 
